Parallel down-regulation of FOXO1, PPARγ and adiponectin mRNA expression in visceral adipose tissue of class III obese individuals

Obesity Facts

Volumn 5, Issue 3, 2012, Pages 452-459

  Hammes, Thais Ortiz ^a   Costa, Cntia Dos Santos ^a   Rohden, Francieli ^a   Margis, Rogério ^a   Almeida, Jussara Carnevale De ^a   Padoin, Alexandre Vontobel ^b   Mottin, Cláudio Cora ^b   Guaragna, Regina Maria ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Adiponectin; Adipose tissue; FOXO1; Obesity

Indexed keywords

ADIPONECTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIRTUIN 1; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGE; ARTICLE; CLINICAL ARTICLE; DOWN REGULATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTRA-ABDOMINAL FAT; MIDDLE AGED; OBESITY; OBESITY, ABDOMINAL; OBESITY, MORBID; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; RNA, MESSENGER; SIRTUIN 1; SUBCUTANEOUS FAT; YOUNG ADULT;

EID: 84863930909     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000339574     Document Type: Article

References (38)

1. Friel S, Chopra M, Satcher D: Unequal weight: Equity oriented policy responses to the global obesity epidemic. BMJ 2007; 335: 1241-1243.
2. Forsythe LK, Wallace JMW, Livingstone MBE: Obesity and inflammation: The effects of weight loss. Nutr Res Rev 2008; 21: 117-133.
3. Lean ME: Pathophysiology of obesity. Proc Nutr Soc 2000; 59: 331-336.
4. Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et al: Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther2008r;6: 343-368.
5. Frederiksen L, Nielsen TL, Wraae K, Hagen C, Frystyk J, Flyvbjerg A, et al: Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab 2009; 94: 4010-4015.
6. Veilleux A, Laberge PY, Morency J, Noël S, Luu-The V, Tchernof A: Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue. J Steroid Biochem Mol Biol 2010; 122: 28-34.
7. Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, et al: PPARs and their metabolic modulation: New mechanisms for transcriptional regulation? J Intern Med 2007; 262: 184-198.
8. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, et al: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597-609.
9. Rogue A, Spire C, Brun M, Claude N, Guillouzo A: Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res 2010 Jan;2010: 325183.
10. Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
11. Côté M, Mauriège P, Bergeron J, Alméras N, Tremblay A, Lemieux I, et al: Adiponectinemia in visceral obesity: Impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005; 90: 1434-1439.
12. Gross DN, Wan M, Birnbaum MJ: The role of FOXO in the regulation of metabolism. Curr Diab Rep 2009; 9: 208-214.
13. Kitamura T, Nakae J, Kitamura Y, Kido Y, Iii WHB, Wright CVE, et al: The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic cell growth. J Clin Invest 2002; 110: 1839-1847.
14. Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 1999; 96: 7421-7426.
15. Armoni M, Harel C, Karni S, Chen H, Bar-Yoseph F, Ver MR, et al: FOXO1 represses peroxisome proliferatoractivated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 2006; 281: 19881-19891.
16. Colak Y, Ozturk O, Senates E, Tuncer I, Yorulmaz E, Adali G, et al: SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 2011; 17:HY5-9.
17. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, et al: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-776.
18. Costa CDS, Hammes TO, Rohden F, Margis R, Bortolotto JW, Padoin AV, et al: SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obes Surg 2010; 20: 633-639.
19. Bäckesjö C-M, Li Y, Lindgren U, Haldosén L-A: Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs 2009; 189: 93-97.
20. Qiao L, Shao J: SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 2006; 281: 39915-39924.
21. Wallace TM, Matthews DR: The assessment of insulin resistance in man. Diab Med 2002; 19: 527-534.
22. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 Dec;25: 402-8.
23. Barth S, Klein P, Horbach T, Dötsch J, Rauh M, Rascher W, et al: Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: Relation to endocrine and clinical parameters. Obes Facts 2010; 3: 245-251.
24. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B: Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15.
25. Drolet R, Bélanger C, Fortier M, Huot C, Mailloux J, Légaré D, et al: Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity (Silver Spring) 2009; 17: 424-430.
26. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, et al: Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diab Res 2000; 1: 81-88.
27. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al: Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
28. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, et al: Regulation of adiponectin by adipose tissue-derived cytokines: In vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285:E527-33.
29. Antuna-Puente B, Feve B, Fellahi S, Bastard J-P: Adipokines: The missing link between insulin resistance and obesity. Diab Metab 2008; 34: 2-11.
30. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-1089.
31. Nakae J, Kitamura T, Kitamura Y, Biggs WH, Arden KC, Accili D: The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 2003; 4: 119-129.
32. Kim JJ, Li P, Huntley J, Chang JP, Arden KC, Olefsky JM: FoxO1 haploinsufficiency protects against high-fat peroxisome proliferator - activated receptor -activation in adipose tissue. Diabetes 2009; 58: 1275-1282.
33. Pang W-J, Yu T-Y, Bai L, Yang Y-J, Yang G-S: Tissue expression of porcine FoxO1 and its negative regulation during primary preadipocyte differentiation. Mol Biol Rep 2009; 36: 165-176.
34. Giusti V, Verdumo C, Suter M, Gaillard RC, Burckhardt P, Pralong F: Expression of peroxisome proliferator - activated tissue of obese women. Diabetes 2003; 52: 1673-1676.
35. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S: Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 2002; 51: 718-723.
36. Salminen A, Ojala J, Huuskonen J, Kauppinen A, Suuronen T, Kaarniranta K: Interaction of aging-associated signaling cascades: Inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci 2008; 65: 1049-1058.
37. Van Der Horst A, Burgering BMT: Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007; 8: 440-450.
38. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, et al: FoxO1 regulates multiple metabolic pathways in the liver: Effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 2006; 281: 10105-10117.